No connection

Search Results

RLYB vs RNXT

RLYB
Rallybio Corporation
BEARISH
Price
$8.22
Market Cap
$43.5M
Sector
Healthcare
AI Confidence
85%
RNXT
RenovoRx, Inc.
BEARISH
Price
$1.00
Market Cap
$45.1M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
RLYB
--
RNXT
--
Forward P/E
RLYB
-1.52
RNXT
-8.33
P/B Ratio
RLYB
0.75
RNXT
6.76
P/S Ratio
RLYB
50.68
RNXT
40.12
EV/EBITDA
RLYB
0.35
RNXT
-3.19

Profitability

Gross Margin
RLYB
0.0%
RNXT
70.88%
Operating Margin
RLYB
-2888.29%
RNXT
-1269.75%
Profit Margin
RLYB
0.0%
RNXT
0.0%
ROE
RLYB
-15.01%
RNXT
-225.62%
ROA
RLYB
-30.07%
RNXT
-92.59%

Growth

Revenue Growth
RLYB
484.2%
RNXT
453.5%
Earnings Growth
RLYB
--
RNXT
--

Financial Health

Debt/Equity
RLYB
0.0
RNXT
0.04
Current Ratio
RLYB
14.51
RNXT
4.02
Quick Ratio
RLYB
12.96
RNXT
3.65

Dividends

Dividend Yield
RLYB
--
RNXT
--
Payout Ratio
RLYB
0.0%
RNXT
0.0%

AI Verdict

RLYB BEARISH

RLYB exhibits critical fundamental weakness, highlighted by a Piotroski F-Score of 0/9, indicating a complete lack of financial health across profitability and efficiency metrics. While the company maintains a strong liquidity position with a Current Ratio of 14.51 and zero debt, its operating margin of -2888.29% and a Price/Sales ratio of 50.68 suggest an unsustainable burn rate and extreme overvaluation relative to current revenue. The recent 1-year price surge appears speculative, as it is decoupled from the deterministic health scores and a bearish technical trend of 0/100.

Strengths
Exceptional short-term liquidity (Current Ratio: 14.51)
Zero debt (Debt/Equity: 0.00)
Explosive year-over-year revenue growth (484.20%)
Risks
Severe operational inefficiency (Operating Margin: -2888.29%)
Critical failure in deterministic health (Piotroski F-Score: 0/9)
Extreme valuation premium on sales (P/S: 50.68)
RNXT BEARISH

RNXT exhibits critical fundamental weakness, highlighted by a Piotroski F-Score of 1/9, indicating severe financial distress and poor operational efficiency. While the company maintains a strong liquidity position with a current ratio of 4.02 and very low debt, it is burning cash at an unsustainable rate with an operating margin of -1269.75%. The valuation is disconnected from fundamentals, trading at a Price/Sales ratio of 40.12. Despite aggressive 'strong buy' analyst targets of $6.88, the deterministic data suggests a high-risk speculative profile with a long-term bearish price trend.

Strengths
Strong short-term liquidity (Current Ratio: 4.02)
Very low leverage (Debt/Equity: 0.04)
Explosive year-over-year revenue growth (453.50%)
Risks
Extreme operational inefficiency (Operating Margin: -1269.75%)
Severe fundamental health failure (Piotroski F-Score: 1/9)
Extreme valuation premium (Price/Sales: 40.12)

Compare Another Pair

RLYB vs RNXT: Head-to-Head Comparison

This page compares Rallybio Corporation (RLYB) and RenovoRx, Inc. (RNXT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile